Half of advanced melanoma patients live for 10 years with double drug treatment - The Guardian

* Half of advanced melanoma patients live for 10 years with double drug treatment  The Guardian
* New skin cancer treatment helps patients live 10 years after diagnosis, study finds  The Telegraph
* Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma  BioSpace
* Neoadjuvant Immunotherapy Superior to Targeted Therapy in Stage III Melanoma  AJMC.com Managed Markets Network


http://dlvr.it/TDHLLv